-+ 0.00%
-+ 0.00%
-+ 0.00%

Silence Therapeutics Presents Additional Data Showcasing SANRECO Phase 1 Study Of Divesiran In Patients With PV At EHA 2025 Annual Meeting

Benzinga·06/12/2025 20:02:22
Listen to the news

Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran

Company Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track for Full Enrollment by Year-End 2025

Silence Therapeutics plc ("Silence" or the "Company") (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy.